Avalo Therapeutics (NASDAQ:AVTX) Shares Down 5.4% – Here’s What Happened

Avalo Therapeutics, Inc. (NASDAQ:AVTX)’s share price fell 5.4% during trading on Monday . The company traded as low as $18.37 and last traded at $18.33. Approximately 109,378 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 1,231,273 shares. The stock had previously closed at $19.37.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on AVTX shares. Mizuho upped their target price on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Citizens Jmp dropped their price target on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 14th. Bank of America began coverage on shares of Avalo Therapeutics in a report on Friday, June 12th. They issued a “buy” rating and a $35.00 price target for the company. Weiss Ratings cut shares of Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a report on Wednesday, May 6th. Thirteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Avalo Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $45.80.

Avalo Therapeutics Price Performance

The stock has a market capitalization of $986.11 million, a price-to-earnings ratio of -3.43 and a beta of 0.78. The stock has a 50 day moving average price of $16.85 and a 200-day moving average price of $16.09.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.02. As a group, research analysts forecast that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current year.

Insider Activity

In related news, insider Paul Varki sold 75,063 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the transaction, the insider directly owned 3,634 shares in the company, valued at approximately $73,297.78. The trade was a 95.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 8,457 shares of the company’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $13.23, for a total transaction of $111,886.11. Following the sale, the chief financial officer directly owned 423 shares of the company’s stock, valued at approximately $5,596.29. This represents a 95.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 93,428 shares of company stock worth $1,762,722 over the last three months. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AVTX. Caligan Partners LP purchased a new stake in shares of Avalo Therapeutics in the third quarter valued at approximately $10,592,000. Balyasny Asset Management L.P. purchased a new position in Avalo Therapeutics during the third quarter worth approximately $10,390,000. Vanguard Group Inc. lifted its position in Avalo Therapeutics by 314.9% during the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after buying an additional 525,696 shares in the last quarter. Millennium Management LLC boosted its stake in Avalo Therapeutics by 380.2% during the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock worth $11,985,000 after buying an additional 522,548 shares during the last quarter. Finally, Seven Fleet Capital Management LP grew its holdings in Avalo Therapeutics by 806.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock valued at $8,568,000 after buying an additional 510,540 shares in the last quarter. 87.06% of the stock is owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.